Exelixis (EXEL) Shares Outstanding (Weighted Average) (2010 - 2026)
Exelixis (EXEL) recorded quarterly Shares Outstanding (Weighted Average) of $258.3 million in Q2 2026, down 4.87% quarter-over-quarter from $271.6 million in Q1 2026, and down 7.34% on a YoY basis from $278.8 million in Q2 2025.
Exelixis (EXEL) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends
Exelixis' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $258.3 million for Q2 2026.
- In Q2 2026, Shares Outstanding (Weighted Average) fell 7.34% year-over-year to $258.3 million; the TTM figure through Apr 2026 stood at $258.3 million (down 7.34% YoY), while the FY2026 annual figure was $271.6 million, down 6.37% from the prior year.
- Shares Outstanding (Weighted Average) was $258.3 million for Q2 2026 at Exelixis, down from $271.6 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $324.4 million in Q1 2023 to a low of $258.3 million in Q2 2026.
- Historically, Shares Outstanding (Weighted Average) has averaged $300.4 million across 5 years, with a median of $300.8 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) advanced 2.5% in 2022, then decreased 9.18% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $321.5 million in 2022, then retreated by 1.05% to $318.2 million in 2023, then slipped by 8.26% to $291.9 million in 2024, then declined by 6.37% to $273.3 million in 2025, then dropped by 5.47% to $258.3 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $258.3 million (Q2 2026), $271.6 million (Q1 2026), and $273.3 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 928.40 Mn |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 258.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 258.33 Mn |
| Jan 2, 2026 | 271.57 Mn |
| Oct 3, 2025 | 273.27 Mn |
| Jul 4, 2025 | 275.69 Mn |
| Apr 4, 2025 | 278.80 Mn |
| Jan 3, 2025 | 290.03 Mn |
| Sep 27, 2024 | 291.87 Mn |
| Jun 28, 2024 | 294.99 Mn |
| Mar 29, 2024 | 300.76 Mn |
| Dec 29, 2023 | 318.15 Mn |
| Sep 29, 2023 | 321.37 Mn |
| Jun 30, 2023 | 324.31 Mn |
| Mar 31, 2023 | 324.42 Mn |
| Dec 30, 2022 | 321.53 Mn |
| Sep 30, 2022 | 320.95 Mn |
| Jul 1, 2022 | 321.12 Mn |
| Apr 1, 2022 | 319.58 Mn |
| Dec 31, 2021 | 314.88 Mn |
| Oct 1, 2021 | 313.99 Mn |
| Jul 2, 2021 | 313.30 Mn |